Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities analysts also recently weighed in on the company. Morgan Stanley boosted their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday. Needham & Company LLC lifted their target price on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Guggenheim boosted their target price on Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Lake Street Capital restated a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Finally, BTIG Research lifted their price objective on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.57.

Personalis Price Performance

Shares of PSNL stock opened at $9.56 on Friday. The stock has a market cap of $848.93 million, a P/E ratio of -10.86 and a beta of 1.99. The company has a fifty day moving average price of $8.77 and a two-hundred day moving average price of $6.73. Personalis has a one year low of $2.83 and a one year high of $11.40.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.04. The company had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. As a group, equities research analysts anticipate that Personalis will post -1.4 EPS for the current fiscal year.

Insider Activity at Personalis

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the transaction, the chief financial officer owned 164,458 shares in the company, valued at $1,772,857.24. This trade represents a 38.66% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc bought a new stake in Personalis in the 2nd quarter valued at about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Personalis during the second quarter worth approximately $34,000. BNP Paribas Financial Markets raised its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. Focus Partners Wealth bought a new stake in shares of Personalis in the first quarter valued at approximately $47,000. Finally, Alpha Wealth Funds LLC acquired a new stake in Personalis during the second quarter worth approximately $66,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.